PT-141 Injection Rx is a clinician-guided libido and sexual wellness program. It is designed to support sexual desire, arousal, sexual responsiveness and overall vitality by targeting pathways involved in neurological signaling and physiological response.
PT-141 contains bremelanotide, the same active ingredient found in Vyleesi. Vyleesi is FDA-approved for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Compounded PT-141 is not FDA-approved. A licensed clinician may prescribe it for other uses when medically appropriate.
The program begins with a medical intake and a telehealth consultation with a licensed clinician. If appropriate, a personalized protocol is prescribed based on individual needs. Treatment may be fulfilled through licensed providers and pharmacies where permitted.
- Active ingredient
- Bremelanotide
- Form
- Injection
- Access
- Prescription only, after medical intake and telehealth consultation with a licensed clinician
- Supports
- Libido and sexual desire, arousal pathways, sexual responsiveness, overall vitality and confidence
- FDA status
- Compounded PT-141 is not FDA-approved. Vyleesi, with the same active ingredient, is FDA-approved for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder.
- Dosing limit
- No more than one dose within 24 hours and no more than eight doses per month
- Do not use if
- Uncontrolled hypertension, known cardiovascular disease, pregnancy or breastfeeding
- Effects
- Can temporarily increase blood pressure and reduce heart rate
- Common reactions
- Nausea, flushing, headache, fatigue, injection-site reactions
- Clinician review
- Required for drug interactions and for liver or kidney impairment